|Day Low/High||612.20 / 644.34|
|52 Wk Low/High||271.37 / 655.93|
Stock still needs a period of base building to support advance.
Thanks to the stock market correction many world-class stocks are back down to attractive levels.
Stocks put in broad gains supported by tax cuts, bonuses, a weaker dollar and more.
These favorite names in the volatile sector offer the potential for high rewards.
Traders and investors should stand aside until the situation with this biotech name offers a better entry point.
Upcoming catalysts will redefine the biotech market -- and here are 3 names that will feel the impact.
The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.
Many swings on a particular chart tend to be similar to others.
Shares have regained their 50-day moving average and look likely to push higher.
Dips in the pharma name have been bought, a sign of demand that presents a relatively low-risk buying opportunity.
This stock is testing resistance and could push back up to last year's highs.
There are nearly too many surging sectors to count.
Icahn may have a tough time finding interest in this behemoth.